| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $95M | ||
| $91M |
Buys | $19,999 | 1 | 100 |
Sells | $0 | 0 | 0 |
| Rajagopalan Harith | Chief Executive Officer | 1 | $19,999 | 0 | $0 | $19,999 |
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.
Over the last 12 months, insiders at Fractyl Health, Inc. Common Stock have bought $19,999 and sold $0 worth of Fractyl Health, Inc. Common Stock stock.
On average, over the past 5 years, insiders at Fractyl Health, Inc. Common Stock have bought $2.51M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Rajagopalan Harith (Chief Executive Officer) — $19,999.
The last purchase of 10,416 shares for transaction amount of $19,999 was made by Rajagopalan Harith (Chief Executive Officer) on 2025‑12‑04.
| 2025-12-04 | Rajagopalan Harith | Chief Executive Officer | 10,416 0.0136% | $1.92 | $19,999 | -67.02% | ||
| 2024-02-06 | CVF, LLC | 10 percent owner | 333,333 3.4012% | $15.00 | $5M | -67.50% |
| Rajagopalan Harith | Chief Executive Officer | 501745 0.695% | $340,484.16 | 1 | 0 | |
| CVF, LLC | 10 percent owner | 4673870 6.4741% | $3.17M | 1 | 0 | <0.0001% |
$2,542,362 | 111 | 11.81% | $54.57M | |
$155,630,608 | 79 | -24.53% | $54.18M | |
$693,326 | 47 | -16.18% | $49.93M | |
$4,898,715 | 46 | 40.75% | $57.34M | |
$24,478,755 | 37 | -34.59% | $56.18M | |
$226,127 | 22 | -27.62% | $48.55M | |
$26,786,140 | 22 | -18.62% | $56.93M | |
$3,556,951 | 18 | 9.64% | $41.07M | |
$17,594,514 | 16 | -20.37% | $59.14M | |
$277,862 | 15 | 59.79% | $58.09M | |
$31,610,161 | 9 | -73.83% | $46.07M | |
$45,000,000 | 6 | -31.22% | $54.73M | |
$5,306,958 | 5 | 11.70% | $44.15M | |
$104,699 | 5 | -12.61% | $38.49M | |
$208,889 | 5 | 44.22% | $46.08M | |
$67,369,250 | 3 | -22.09% | $45.13M | |
$4,030 | 1 | 9.14% | $43.52M | |
Fractyl Health, Inc. Common Stock (GUTS) | $4,999,995 | 1 | -67.50% | $48.99M |
$150,000 | 1 | 5.48% | $45.8M |
| Increased Positions | 65 | +92.86% | 38M | +41.52% |
| Decreased Positions | 28 | -40% | 16M | -17.76% |
| New Positions | 33 | New | 15M | New |
| Sold Out Positions | 8 | Sold Out | 702,123 | Sold Out |
| Total Postitions | 107 | +52.86% | 112M | +23.76% |